Acelyrin Inc is a late-stage clinical biopharmaceutical company... Show more
Get AI intraday signals
A.I. Advisor
published Earnings
SLRN is expected to report earnings to rise 42.83% to -126 cents per share on June 12
Q1'25
Est.
$-1.27
Q4'24
Beat
by $0.52
Q3'24
Beat
by $0.70
Q2'24
Beat
by $0.22
Q1'24
Beat
by $0.65
The last earnings report on March 27 showed earnings per share of -88 cents, beating the estimate of -140 cents. With 2.66M shares outstanding, the current market capitalization sits at 275.94M.